Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Focal Prostate Ablation for Low to Intermediate Grade Cancer Utilizing TULSA Profound System

NCT05438563 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05438563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05438563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Focal Prostate Ablation for Low to Intermediate Grade Cancer Utilizing TULSA Profound System
Lead sponsor
Mayo Clinic
Phase
Not applicable
Overall status
Recruiting
Start date
April 6, 2022
Completion date
December 7, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate carcinoma, stage i prostate cancer ajcc v8, stage ii prostate cancer ajcc v8